FLOTOR Pilot Study

Esophageal Cancer Clinical Trial

— FLOTOR  

Official title:

FLuOrescence to Identify the Thoracic Duct During Oesophageal Resections

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03292757
• Other study ID #: 12968
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 20, 2017
• Est. completion date: September 20, 2018

Study information

• Verified date: November 2018
• Source: Oxford University Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomised study assessing the technique of using indocyanine green as a fluorescent dye to highlight the thoracic duct during oesophectomy.

Description:

The thoracic duct is the largest vessel of the lymphatic system in the body. It transports chyle (a liquid containing both lymph and emulsified fats) from most of the body, including the gastrointestinal tract, into the left internal jugular vein. It is largely located in the thorax and is at risk of injury during the thoracic part of an oesophagectomy.

The reported incidence of thoracic duct injury during oesophagectomy is between 0.2 and 10.5%, although it may be under-reported in the literature. A review of prospective collected complication data from 292 consecutive oesophagectomies performed in Oxford over a 5 year period revealed a chyle leak rate of 9.9%. Chyle leak was associated in a doubling of median length of post-operative stay from 8 to 16 days in these patients. Chylothorax has been associated with a mortality of up to 30%.

Over the years, a number of attempts have been made to visualise chyle leakage following thoracic duct injury including administration of enteral fat containing feed (e.g. double cream), methylene blue and lymphoscintigraphy, but no studies have been published showing a mechanism to aid thoracic duct identification at the index operation, and so prevent injuries.

Fluorescence is a technique which uses fluorescent dyes (fluorophores) that emit invisible (near infra-red (NIR)) light when they are excited by light at a particular wavelength. In order to use this technique, a fluorescence-enabled camera is required in order to shine light at that particular wavelength on the fluorophore and to capture the light emitted. This is then displayed on a screen for the surgeon to see.

Indocyanine green (ICG) is a fluorescent molecule that is approved by the FDA (Food and Drug Administration) and the MHRA for use in humans. It is a widely used near infra-red dye for numerous operations. Near infra-red guided lymphatic mapping with ICG has gained much attention over recent years and its use has widely been published in breast and colorectal surgery. ICG has also been successfully used to identify the thoracic duct in a number of case reports in both adults and children.

ICG can be injected into the small bowel mesentery to aid identification of thoracic duct injury at re-exploration. This study aims to assess the feasibility of using ICG fluorescence to identify the thoracic duct during oesophagectomy, with the eventual aim of developing its routine use to prevent thoracic duct injuries.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: September 20, 2018
• Est. primary completion date: August 20, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant is willing and able to give informed consent for participation in the study.

• Male or Female, aged 18 years or above.

• Undergoing elective oesophagectomy

Exclusion Criteria:

• Known allergy to iodine or ICG

• Female patient who is pregnant, planning pregnancy or breastfeeding

• Patient has a lactose intolerance (excluded only from receiving cream method)

• Known significant liver failure

Related Conditions & MeSH terms

• Chylothorax
• Esophageal Cancer
• Esophageal Neoplasms
• Thoracic Duct Intra-Operative Injury

Intervention

Drug:
• Indocyanine Green
Fluorescent dye - indocyanine green

Locations

Country	Name	City	State
United Kingdom	Department of Upper GI Surgery, Oxford University Hospitals	Headington	Oxfordshire

Sponsors (1)

Lead Sponsor	Collaborator
Oxford University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of thoracic ducts seen under fluorescence versus number of thoracic ducts seen with white light. (Change over time)	Thoracic duct visualised fluorescence assessment	0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 180, 240 minutes post dose
Secondary	Signal to background ratio of fluorescence in thoracic ducts between 2 methods of ICG administration.	Thoracic duct fluorescence levels between methods of ICG administration	0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 180, 240 minutes post dose
Secondary	Signal to background ratio of fluorescence in thoracic ducts between dosing levels.	Thoracic duct fluorescence levels between ICG doses	0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 180, 240 minutes post dose